RU2017115885A - Терапевтические агенты для лечения людей - Google Patents
Терапевтические агенты для лечения людей Download PDFInfo
- Publication number
- RU2017115885A RU2017115885A RU2017115885A RU2017115885A RU2017115885A RU 2017115885 A RU2017115885 A RU 2017115885A RU 2017115885 A RU2017115885 A RU 2017115885A RU 2017115885 A RU2017115885 A RU 2017115885A RU 2017115885 A RU2017115885 A RU 2017115885A
- Authority
- RU
- Russia
- Prior art keywords
- component
- group
- isovaniline
- composition
- specified
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 6
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 148
- JVTZFYYHCGSXJV-UHFFFAOYSA-N isovanillin Chemical compound COC1=CC=C(C=O)C=C1O JVTZFYYHCGSXJV-UHFFFAOYSA-N 0.000 claims 114
- BXNJHAXVSOCGBA-UHFFFAOYSA-N Harmine Chemical compound N1=CC=C2C3=CC=C(OC)C=C3NC2=C1C BXNJHAXVSOCGBA-UHFFFAOYSA-N 0.000 claims 101
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims 92
- 125000004185 ester group Chemical group 0.000 claims 49
- 235000012754 curcumin Nutrition 0.000 claims 46
- 229940109262 curcumin Drugs 0.000 claims 46
- 239000004148 curcumin Substances 0.000 claims 46
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims 46
- RERZNCLIYCABFS-UHFFFAOYSA-N Harmaline hydrochloride Natural products C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 claims 44
- 150000007942 carboxylates Chemical group 0.000 claims 34
- 229930014626 natural product Natural products 0.000 claims 34
- 125000003368 amide group Chemical group 0.000 claims 31
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 31
- 150000003462 sulfoxides Chemical class 0.000 claims 31
- 229910052736 halogen Inorganic materials 0.000 claims 29
- 150000002367 halogens Chemical class 0.000 claims 29
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 29
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 28
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims 25
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 23
- 125000001424 substituent group Chemical group 0.000 claims 23
- VJHLDRVYTQNASM-UHFFFAOYSA-N harmine Natural products CC1=CN=CC=2NC3=CC(=CC=C3C=21)OC VJHLDRVYTQNASM-UHFFFAOYSA-N 0.000 claims 22
- 230000001225 therapeutic effect Effects 0.000 claims 22
- 150000001299 aldehydes Chemical group 0.000 claims 21
- -1 amino, carbonyl Chemical group 0.000 claims 21
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 201000011510 cancer Diseases 0.000 claims 20
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 19
- 125000003118 aryl group Chemical group 0.000 claims 19
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 19
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 18
- 238000011282 treatment Methods 0.000 claims 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 16
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 14
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 14
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 14
- 229930182480 glucuronide Natural products 0.000 claims 14
- 150000008134 glucuronides Chemical class 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 13
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 238000000034 method Methods 0.000 claims 12
- RHVPEFQDYMMNSY-UHFFFAOYSA-N Harmalol Natural products N1C2=CC(O)=CC=C2C2=C1C(C)=NCC2 RHVPEFQDYMMNSY-UHFFFAOYSA-N 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 229910052796 boron Inorganic materials 0.000 claims 10
- 125000004432 carbon atom Chemical group C* 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- IQZPDFORWZTSKT-UHFFFAOYSA-N nitrosulphonic acid Chemical compound OS(=O)(=O)[N+]([O-])=O IQZPDFORWZTSKT-UHFFFAOYSA-N 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims 10
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims 10
- 235000012141 vanillin Nutrition 0.000 claims 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 8
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 8
- 150000001450 anions Chemical class 0.000 claims 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 125000004429 atom Chemical group 0.000 claims 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 8
- 239000001301 oxygen Substances 0.000 claims 8
- 239000011593 sulfur Substances 0.000 claims 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 7
- 125000005647 linker group Chemical group 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 230000001093 anti-cancer Effects 0.000 claims 6
- 238000011319 anticancer therapy Methods 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 229910017604 nitric acid Inorganic materials 0.000 claims 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 4
- QPDFBPIHEDAUKK-UHFFFAOYSA-N 2-bromo-3-hydroxy-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(Br)=C1O QPDFBPIHEDAUKK-UHFFFAOYSA-N 0.000 claims 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 4
- PSFDQSOCUJVVGF-UHFFFAOYSA-N harman Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C PSFDQSOCUJVVGF-UHFFFAOYSA-N 0.000 claims 4
- ZUPHXNBLQCSEIA-UHFFFAOYSA-N (1xi,3xi)-1,2,3,4-Tetrahydro-1-methyl-beta-carboline-3-carboxylic acid Chemical compound N1C2=CC=CC=C2C2=C1C(C)NC(C(O)=O)C2 ZUPHXNBLQCSEIA-UHFFFAOYSA-N 0.000 claims 3
- KLSHZDPXXKAHIJ-UHFFFAOYSA-N 3-bromo-4-hydroxy-5-methoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(Br)=C1O KLSHZDPXXKAHIJ-UHFFFAOYSA-N 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- LBKFGYZQBSGRHY-UHFFFAOYSA-N iso-vanillic acid Natural products COC1=CC=C(C(O)=O)C=C1O LBKFGYZQBSGRHY-UHFFFAOYSA-N 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 150000007659 semicarbazones Chemical class 0.000 claims 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 125000006799 (C2-C6) alkenylamino group Chemical group 0.000 claims 2
- KLXKKFGRNPBWGM-UHFFFAOYSA-N 3-hydroxy-2-iodo-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(I)=C1O KLXKKFGRNPBWGM-UHFFFAOYSA-N 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical group OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 2
- 150000001266 acyl halides Chemical class 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 2
- 125000001769 aryl amino group Chemical group 0.000 claims 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 125000003262 carboxylic acid ester group Chemical class [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 claims 2
- 125000000262 haloalkenyl group Chemical group 0.000 claims 2
- CRQDWQWZCNKKAC-UHFFFAOYSA-N harmalol Chemical compound N1C2=CC(=O)C=CC2=C2C1=C(C)NCC2 CRQDWQWZCNKKAC-UHFFFAOYSA-N 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims 2
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 claims 2
- YNVAHBUBGBLIEY-WGDLNXRISA-N (1e,4e)-1,5-bis(2-hydroxyphenyl)penta-1,4-dien-3-one Chemical compound OC1=CC=CC=C1\C=C\C(=O)\C=C\C1=CC=CC=C1O YNVAHBUBGBLIEY-WGDLNXRISA-N 0.000 claims 1
- VXKNQOUEXUHOLI-KQQUZDAGSA-N (1e,4e)-1,5-bis(3,5-dimethoxyphenyl)penta-1,4-dien-3-one Chemical compound COC1=CC(OC)=CC(\C=C\C(=O)\C=C\C=2C=C(OC)C=C(OC)C=2)=C1 VXKNQOUEXUHOLI-KQQUZDAGSA-N 0.000 claims 1
- MAMZRGWIDSXSNU-UHFFFAOYSA-N 1-(2-hydroxyphenyl)penta-1,4-dien-3-one Chemical compound OC1=CC=CC=C1C=CC(=O)C=C MAMZRGWIDSXSNU-UHFFFAOYSA-N 0.000 claims 1
- LBBJNGFCXDOYMQ-UHFFFAOYSA-N 1-methyl-2,9-dihydropyrido[3,4-b]indol-7-one Chemical compound C1=CC(=O)C=C2NC3=C(C)NC=CC3=C21 LBBJNGFCXDOYMQ-UHFFFAOYSA-N 0.000 claims 1
- SATMZMMKDDTOSQ-UHFFFAOYSA-N Harmol Natural products C12=CC=C(O)C=C2NC2=C1C=CN=C2C SATMZMMKDDTOSQ-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000005189 alkyl hydroxy group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 claims 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462066686P | 2014-10-21 | 2014-10-21 | |
| US62/066,686 | 2014-10-21 | ||
| US201562161090P | 2015-05-13 | 2015-05-13 | |
| US62/161,090 | 2015-05-13 | ||
| US14/721,011 US9402834B2 (en) | 2014-10-21 | 2015-05-26 | Human therapeutic agents |
| US14/721,011 | 2015-05-26 | ||
| US201562184051P | 2015-06-24 | 2015-06-24 | |
| US62/184,051 | 2015-06-24 | ||
| PCT/US2015/055968 WO2016064676A1 (en) | 2014-10-21 | 2015-10-16 | Human therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2017115885A true RU2017115885A (ru) | 2018-11-23 |
Family
ID=55761352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017115885A RU2017115885A (ru) | 2014-10-21 | 2015-10-16 | Терапевтические агенты для лечения людей |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP3188721B1 (enExample) |
| JP (1) | JP6937237B2 (enExample) |
| KR (1) | KR20170066425A (enExample) |
| CN (3) | CN107106519B (enExample) |
| AU (1) | AU2015336311B2 (enExample) |
| CA (1) | CA2955114C (enExample) |
| DK (1) | DK3188721T3 (enExample) |
| ES (1) | ES2744913T3 (enExample) |
| IL (1) | IL250990A0 (enExample) |
| MX (1) | MX2017002489A (enExample) |
| RU (1) | RU2017115885A (enExample) |
| TW (1) | TW201625230A (enExample) |
| WO (1) | WO2016064676A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016181220A2 (en) * | 2015-05-13 | 2016-11-17 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions and methods of use thereof |
| JP2021510153A (ja) | 2018-01-05 | 2021-04-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物 |
| US11246902B2 (en) | 2018-02-23 | 2022-02-15 | Ankh Life Sciences Limited | Nutritional supplement for mammals |
| WO2019183245A1 (en) | 2018-03-20 | 2019-09-26 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| US10875859B2 (en) | 2018-04-13 | 2020-12-29 | Ankh Life Sciences Limited | Thymoquinone/harmaline and related reaction products |
| US11453664B2 (en) | 2018-04-13 | 2022-09-27 | Ankh Life Sciences Limited | Thymoquinone/harmaline and related reaction products |
| US11453665B2 (en) | 2018-04-13 | 2022-09-27 | Ankh Life Sciences Limited | Thymoquinone/harmaline and related reaction products |
| US11452715B2 (en) | 2018-04-13 | 2022-09-27 | Ankh Life Sciences Limited | Thymoquinone/harmaline and related reaction products |
| US10947253B2 (en) | 2019-08-05 | 2021-03-16 | Ankh Life Sciences Limited | Fused polycyclic dimers |
| US12419872B2 (en) | 2020-03-05 | 2025-09-23 | Ankh Life Sciences Limited | Low-temperature synthesis of thymoquinone and harmaline compounds |
| US12129265B2 (en) | 2020-07-21 | 2024-10-29 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
| WO2022019892A1 (en) * | 2020-07-21 | 2022-01-27 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
| JP2023080697A (ja) * | 2021-11-30 | 2023-06-09 | 株式会社渡辺オイスター研究所 | 転移性ヒト前立腺がん細胞の増殖抑制剤 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54126731A (en) * | 1978-03-20 | 1979-10-02 | Rikagaku Kenkyusho | Carcinostatic agent |
| US7355081B2 (en) * | 2002-04-17 | 2008-04-08 | The University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
| JP2004075666A (ja) * | 2002-05-15 | 2004-03-11 | Keio Gijuku | 造血器腫瘍の治療薬、免疫抑制剤、およびｐ５３を標的分子とする分子標的治療薬 |
| CN100503607C (zh) * | 2003-06-02 | 2009-06-24 | 新疆华世丹药物研究有限责任公司 | 去氢骆驼蓬碱衍生物类化合物及其应用 |
| FR2869540B1 (fr) * | 2004-04-30 | 2008-05-16 | Centre Nat Rech Scient Cnrse | Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers |
| CN100553628C (zh) * | 2005-08-25 | 2009-10-28 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 2-溴-异香兰素在制备抗癌和/或辐射、化疗增敏药物中的应用 |
| US8735154B2 (en) | 2006-10-30 | 2014-05-27 | The University Of Kansas | Templated islet cells and small islet cell clusters for diabetes treatment |
| WO2008150899A1 (en) * | 2007-05-29 | 2008-12-11 | Emory University | Combination therapies for treatment of cancer and inflammatory diseases |
| CN101669931B (zh) * | 2008-09-08 | 2012-07-04 | 北京鼎国昌盛生物技术有限责任公司 | 长效姜黄素衍生物在制备抗肿瘤症药物中的应用 |
| JP2012524106A (ja) * | 2009-04-15 | 2012-10-11 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 二重ｊａｋ２／ｓｔａｔ３阻害剤としてのクルクミン類似体ならびにその同じ物を作る、および用いる方法 |
| US20130231360A1 (en) * | 2010-04-22 | 2013-09-05 | The Brigham And Women S Hospital, Inc. | Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases |
| US20120058208A1 (en) * | 2010-09-04 | 2012-03-08 | Synthite Industries Ltd. | Synergistic Composition for Enhancing Bioavailability of Curcumin |
| US20120108500A1 (en) * | 2010-10-07 | 2012-05-03 | Naoki Sakane | Compositions and Methods for Modulating Immunodeficiency Virus Transcription |
| US8039025B1 (en) | 2010-10-15 | 2011-10-18 | Life Plus, LLC | Methods and dosage forms for the treatment of human cancers |
| WO2015006646A1 (en) * | 2013-07-11 | 2015-01-15 | Specialty Nutrition Group, Inc. | Compositions comprising hydroxytyrosol, curcumin, and/or astaxanthin and use thereof |
-
2015
- 2015-10-16 EP EP15853030.3A patent/EP3188721B1/en active Active
- 2015-10-16 CN CN201580057827.9A patent/CN107106519B/zh active Active
- 2015-10-16 KR KR1020177009791A patent/KR20170066425A/ko not_active Withdrawn
- 2015-10-16 AU AU2015336311A patent/AU2015336311B2/en active Active
- 2015-10-16 DK DK15853030.3T patent/DK3188721T3/da active
- 2015-10-16 CN CN202210871857.5A patent/CN115569136A/zh active Pending
- 2015-10-16 ES ES15853030T patent/ES2744913T3/es active Active
- 2015-10-16 WO PCT/US2015/055968 patent/WO2016064676A1/en not_active Ceased
- 2015-10-16 CA CA2955114A patent/CA2955114C/en active Active
- 2015-10-16 EP EP17185821.0A patent/EP3275465B1/en active Active
- 2015-10-16 CN CN201911016462.1A patent/CN110772512A/zh active Pending
- 2015-10-16 JP JP2017522542A patent/JP6937237B2/ja active Active
- 2015-10-16 RU RU2017115885A patent/RU2017115885A/ru not_active Application Discontinuation
- 2015-10-16 MX MX2017002489A patent/MX2017002489A/es unknown
- 2015-10-21 TW TW104134465A patent/TW201625230A/zh unknown
-
2017
- 2017-03-07 IL IL250990A patent/IL250990A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017006190A2 (pt) | 2017-12-26 |
| EP3188721A1 (en) | 2017-07-12 |
| JP2017531689A (ja) | 2017-10-26 |
| AU2015336311A2 (en) | 2020-02-06 |
| DK3188721T3 (da) | 2019-08-12 |
| IL250990A0 (en) | 2017-04-30 |
| EP3188721B1 (en) | 2019-06-12 |
| CA2955114C (en) | 2023-01-03 |
| TW201625230A (zh) | 2016-07-16 |
| AU2015336311A1 (en) | 2017-02-09 |
| ES2744913T3 (es) | 2020-02-26 |
| KR20170066425A (ko) | 2017-06-14 |
| MX2017002489A (es) | 2017-09-13 |
| WO2016064676A1 (en) | 2016-04-28 |
| EP3188721A4 (en) | 2018-05-02 |
| CN115569136A (zh) | 2023-01-06 |
| CN107106519A (zh) | 2017-08-29 |
| JP6937237B2 (ja) | 2021-09-22 |
| AU2015336311B2 (en) | 2020-05-14 |
| CA2955114A1 (en) | 2016-04-28 |
| CN110772512A (zh) | 2020-02-11 |
| EP3275465A1 (en) | 2018-01-31 |
| EP3275465B1 (en) | 2020-05-06 |
| CN107106519B (zh) | 2023-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017115885A (ru) | Терапевтические агенты для лечения людей | |
| JP2017531689A5 (enExample) | ||
| JP2015522650A5 (enExample) | ||
| EA201001821A1 (ru) | Производные триазола, полезные для лечения заболеваний | |
| AR083842A1 (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a las angiogenesis | |
| EA200870282A1 (ru) | Производные амина | |
| JP2016513696A5 (enExample) | ||
| EP4458348A3 (en) | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof | |
| JP2016506916A5 (enExample) | ||
| JP2014503574A5 (enExample) | ||
| CY1117576T1 (el) | Δινουκλεοτιδικα προφαρμακα | |
| JP2017531041A5 (enExample) | ||
| CY1119015T1 (el) | 4'-αζιδο-3'φθορο υποκατεστημενα νουκλεοζιδιου παραγωγα ως αναστολεις αντιγραφης hcv rna | |
| RU2007124329A (ru) | ПРОИЗВОДНЫЕ 5-ГИДРОКСИБЕНЗОТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНОРЕЦЕПТОРОВ | |
| EA200601897A1 (ru) | Производные тетрагидронафтиридина, пригодные в качестве лигандов рецептора н3 гистамина | |
| JP2016516043A5 (enExample) | ||
| RU2013148922A (ru) | Три- и тетрациклические пиразоло[3,4-в]пиридины в качестве антинеопластического средства | |
| JP2014510774A5 (enExample) | ||
| JP2015531773A5 (enExample) | ||
| RU2015106434A (ru) | Производные типа азаиндазола или диазаиндазола для лечения боли | |
| CN117157299A8 (zh) | 三环杂环衍生物及其组合物和应用 | |
| CN108026053A8 (zh) | 作为mIDH1抑制剂的稠合的咪唑类化合物 | |
| SA523441335B1 (ar) | cGAS مركبات وتركيبات لعلاج حالات مرضية مرتبطة بـ | |
| RU2016137668A (ru) | Новые производные каннабидиол-хинона | |
| EA200601868A1 (ru) | 3- или 4-монозамещённые производные фенола и тиофенола, полезные в качестве н-лигандов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20181017 |